Loading…
Matinas Biopharma Holdings is projected to rise to $1.01 by 2027, a +39% move from its current price of $0.73. MTNB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.6985 | $0.7295 | $0.7618 | -0.07% |
| May 30 | $0.6856 | $0.729 | $0.7751 | -0.14% |
| May 31 | $0.6757 | $0.7285 | $0.7853 | -0.21% |
| Jun 1 | $0.6674 | $0.728 | $0.794 | -0.28% |
| Jun 2 | $0.6602 | $0.7275 | $0.8016 | -0.35% |
| Jun 3 | $0.6536 | $0.7269 | $0.8085 | -0.42% |
| Jun 4 | $0.6476 | $0.7264 | $0.8148 | -0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6476 | $0.7264 | $0.8148 | -0.49% |
| Week 2 | $0.6145 | $0.7229 | $0.8503 | -0.97% |
| Week 3 | $0.5896 | $0.7194 | $0.8776 | -1.46% |
| Week 4 | $0.569 | $0.7158 | $0.9006 | -1.94% |
| Week 5 | $0.5511 | $0.7123 | $0.9208 | -2.42% |
| Week 6 | $0.5351 | $0.7089 | $0.9391 | -2.90% |
| Week 7 | $0.5206 | $0.7054 | $0.9558 | -3.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company that identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.
It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Matinas BioPharma Holdings, Inc. (MTNB) is currently priced at $0.7041 and has a market capitalization of $4.51M, with a rank of 5372.
The 2026 forecast shows an average price of $0.7041, with a min of $0.49, a max of $1.08, and an ROI of 0%, and a sentiment labeled NEUTRAL.
From 2027 onward, the forecast shifts to bullish, with the average price rising to $0.9617 in 2027 and continuing higher toward $3.87 by 2050, while max values reach $8.90 and ROI climbs to 449.7% in 2050. The outlook signals meaningful upside over the longer term, tempered by the inherent uncertainty of forecasts.
A major floor 42.1% below — a decisive break under it would weaken the trend.
The nearest floor, 31.5% below — buyers have tended to step in here.
Price is pressing into resistance (0.1% away) — a breakout level to watch.
A major ceiling 21.2% above — clearing it would confirm fresh momentum.
Key MTNB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MTNB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.6942 | Buy | $0.6923 | Buy |
| MA 10 | $0.6265 | Buy | $0.6597 | Buy |
| MA 20 | $0.637 | Buy | $0.6343 | Buy |
| MA 50 | $0.5913 | Buy | $0.6177 | Buy |
| MA 100 | $0.6125 | Buy | $0.678 | Buy |
| MA 200 | $1.01 | Sell | $0.9261 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.61 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 135.47 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 14.58 | Buy |
| Bollinger %B (20,2) | 0.92 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.34 | Buy |
| Awesome (5,34) | 0.09 | Buy |
| Ultimate (7,14,28) | 77.11 | Sell |
| Momentum (10) | 0.14 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 0.75 | Sell |
| ADX (14) | 18.91 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is bullish, with sentiment labeled BULLISH and RSI14 at 60. The SMA50 is $0.5873 and the SMA200 is $1.01, suggesting near-term support around the mid-$0.50s and resistance at $0.704.
An explicit 30-day price range is reported as a low of $0.5216 and a high of $0.9505, reflecting noticeable but contained movement within a tight band. The stock’s annualized volatility is high, listed at 90%, indicating substantial intra- to inter-month swings.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.49 | $0.73 | $1.13 | 0% | Neutral | |
| $0.7574 | $1.01 | $1.46 | +39% | Bullish | |
| $0.8322 | $1.17 | $1.77 | +60% | Bullish | |
| $0.7953 | $1.16 | $1.83 | +59% | Bullish | |
| $0.7831 | $1.18 | $1.93 | +62% | Bullish | |
| $0.7287 | $1.14 | $1.91 | +56% | Bullish | |
| $0.7086 | $1.14 | $1.97 | +56% | Bullish | |
| $0.9092 | $1.51 | $2.67 | +106% | Bullish | |
| $1.06 | $1.81 | $3.27 | +148% | Bullish | |
| $1.09 | $1.91 | $3.53 | +162% | Bullish | |
| $1.17 | $2.35 | $4.70 | +221% | Bullish | |
| $1.98 | $4.40 | $9.92 | +502% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.49 | $0.73 | $0.8564 | +0.00% |
| June 2026 | $0.5661 | $0.6735 | $0.8264 | -7.75% |
| July 2026 | $0.568 | $0.6849 | $0.8582 | +1.70% |
| August 2026 | $0.6018 | $0.7335 | $0.9339 | +7.10% |
| September 2026 | $0.5955 | $0.7323 | $0.9444 | -0.17% |
| October 2026 | $0.5956 | $0.7384 | $0.9634 | +0.83% |
| November 2026 | $0.6452 | $0.8056 | $1.06 | +9.11% |
| December 2026 | $0.6738 | $0.8472 | $1.13 | +5.16% |
Click any year to see its month-by-month MTNB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MTNB is projected to trade between $0.49 and $1.13, averaging $0.73 — a potential gain of 0% from today's $0.73. Price action looks broadly range-bound.
Matinas Biopharma Holdings's 2027 outlook centres on $1.01, within a $0.7574 to $1.46 range. That is up +39% on the projected 2026 average. That marks a +39% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, MTNB could reach as high as $1.77, with a base case around $1.17 and support toward $0.8322 — roughly +60% from $0.73. Momentum favours further upside here.
Expect MTNB to range from $0.7953 to $1.83 through 2029. The $1.16 average target implies a +59% move from current prices. That is -1% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The MTNB price prediction for 2030 points to an average of $1.18 (low $0.7831, high $1.93) — a potential gain of +62% on today's $0.73. Momentum favours further upside here.
In 2031, MTNB is projected to trade between $0.7287 and $1.91, averaging $1.14 — a potential gain of +56% from today's $0.73. That is -4% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
Matinas Biopharma Holdings's 2032 outlook centres on $1.14, within a $0.7086 to $1.97 range. That is up 0% on the projected 2031 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2033, MTNB could reach as high as $2.67, with a base case around $1.51 and support toward $0.9092 — roughly +106% from $0.73. Buyers look set to stay in control over this stretch.
Expect MTNB to range from $1.06 to $3.27 through 2034. The $1.81 average target implies a +148% move from current prices. That is up +20% on the projected 2033 average. Momentum favours further upside here.
The MTNB price prediction for 2035 points to an average of $1.91 (low $1.09, high $3.53) — a potential gain of +162% on today's $0.73. Buyers look set to stay in control over this stretch.
In 2040, MTNB is projected to trade between $1.17 and $4.70, averaging $2.35 — a potential gain of +221% from today's $0.73. That is up +23% on the projected 2035 average. Momentum favours further upside here.
Matinas Biopharma Holdings's 2050 outlook centres on $4.40, within a $1.98 to $9.92 range. That is up +87% on the projected 2040 average. That marks a +502% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MTNB today (≈ 1,369.863014 MTNB) could be worth
$6,020.77
+$5,020.77 (+502%) by 2050 · US Dollar
Based on the average projected MTNB price of $4.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MTNBwould be worth at today's price.
$1,000 invested in MTNB on May 27, 2025 (≈ 1,249.999981 MTNB) would be worth
$912.5
-$87.5 (-8.8%) today · 0.91× · US Dollar
Based on a MTNB entry price of $0.8 vs. today's $0.73.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.638 | $1,144.2 | +14.4% |
| 1 month ago | $0.61 | $1,196.72 | +19.7% |
| 3 months ago | $0.602 | $1,212.62 | +21.3% |
| 6 months ago | $0.75 | $973.33 | -2.7% |
| 1 year ago | $0.8 | $912.5 | -8.8% |
| All time (5.0y) ago | $39.5 | $18.48 | -98.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MTNB forecast.
Our base-case forecast reaches $1.50 around 2033.
Implied market cap at $1.50: $9.61M
Over the multi-year horizon, the forecast shows a clear bullish tilt with rising average prices and sizable potential ROI. In 2027 the avg is $0.9617 with a 36.6% ROI, rising through 2028 at $1.13 (60.4%), 2029 at $1.10 (56%), and 2030 at $1.11 (57.1%). By 2033 the avg grows to $1.37 with a 94.3% ROI, and 2034 sees $1.67 (137.4%).
The 2040 forecast projects an avg of $2.09 and a 196.8% ROI, while 2050 shows an avg of $3.87 with a 449.7% ROI.
The sentiment remains BULLISH across the longer horizon, with forecasted upside driven by higher average prices in later years. These figures are estimates, not guarantees, and actual results can differ due to market conditions and other factors.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $1.11, with a min of $0.7213 and a max of $1.83, and a projected ROI of 57.1%. The sentiment is BULLISH.
Forecasts show bullish sentiment from 2027 onward, with the avg price moving from $0.9617 in 2027 to $3.87 by 2050 and ROI up to 449.7%, though the 2026 outlook is NEUTRAL with an avg price of $0.7041 and ROI of 0%.
The 2040 max forecast is $4.28, which exceeds $4, while the 2040 avg is $2.09 and the min is not shown here. This indicates a potential to surpass $4 in some scenarios, but it remains an estimate.
Current price is $0.7041 and market cap is $4.51M.
The 30-day range is from a low of $0.5216 to a high of $0.9505.
Matinas Biopharma Holdings Community Discussion
0Share your Matinas Biopharma Holdings price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.